Novel hybrids from N-hydroxyarylamide and indole ring through click chemistry as histone deacetylase inhibitors with potent antitumor activities

被引:30
作者
Cai, Mao [1 ]
Hu, Jie [2 ]
Tian, Ji-Lai [3 ]
Yan, Huang [1 ]
Zheng, Chen-Guo [1 ]
Hu, Wan-Le [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Dept Coloproctol, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Dept Pharm, Wenzhou 325000, Peoples R China
[3] Southeast Univ, Sch Biol Sci & Med Engn, Jiangsu Key Lab Biomat & Devices, Nanjing 210008, Jiangsu, Peoples R China
关键词
Synthesis; Anti-tumor agents; Histone deacetylase inhibitors; N-Hydroxyarylamides; Click chemistry; BIOLOGICAL EVALUATION; PHASE-I; CANCER; CYCLOADDITION; MECHANISMS; THERAPY;
D O I
10.1016/j.cclet.2015.03.015
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Novel hybrid molecules 8a-8o were designed and synthesized by connecting indole ring with N-hydroxyarylamide through alkyl substituted triazole, and their in vitro biological activities were evaluated. It was discovered that most of target compounds showed promising anticancer activities, particularly for 8n, which had a significant HDACs inhibitory and antiproliferative activities comparable to or slightly stronger than SAHA against human carcinoma cells. Furthermore, compound 8n exhibited much better selectivity for HDAC1 over HDAC6 and HDAC8 than SAHA. In addition, compound 8n also could dose-dependently induce cancer cell cycling arrest at G0/G1 phase and promote the expression of the acetylation for histone H3 and tubulin in vitro. Therefore, our novel findings may provide a new framework for the design of new selective HDAC inhibitor for the treatment of cancer. (C) 2015 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:675 / 680
页数:6
相关论文
共 26 条
[1]   Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex [J].
Amato, Jussara ;
Iaccarino, Nunzia ;
Pagano, Bruno ;
Morigi, Rita ;
Locatelli, Alessandra ;
Leoni, Alberto ;
Rambaldi, Mirella ;
Zizza, Pasquale ;
Biroccio, Annamaria ;
Novellino, Ettore ;
Randazzo, Antonio .
FRONTIERS IN CHEMISTRY, 2014, 2
[2]   Genomewide studies of histone deacetylase function in yeast [J].
Bernstein, BE ;
Tong, JK ;
Schreiber, SL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (25) :13708-13713
[3]   Efficient Access to New Chemical Space Through Flow-Construction of Druglike Macrocycles Through Copper-Surface-Catalyzed Azide-Alkyne Cycloaddition Reactions [J].
Bogdan, Andrew R. ;
James, Keith .
CHEMISTRY-A EUROPEAN JOURNAL, 2010, 16 (48) :14506-14512
[4]   Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights [J].
Bose, Prithviraj ;
Dai, Yun ;
Grant, Steven .
PHARMACOLOGY & THERAPEUTICS, 2014, 143 (03) :323-336
[5]   Histone deacetylase inhibitors in cancer treatment:: A review of the clinical toxicity and the modulation of gene expression in cancer cells [J].
Bruserud, O. ;
Stapnes, C. ;
Ersvaer, E. ;
Gjertsen, B. T. ;
Ryningen, A. .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2007, 8 (06) :388-400
[6]   Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824) [J].
Cho, Young Shin ;
Whitehead, Lewis ;
Li, Jianke ;
Chen, Christine H-T. ;
Jiang, Lei ;
Voegtle, Markus ;
Francotte, Eric ;
Richert, Paul ;
Wagner, Trixie ;
Traebert, Martin ;
Lu, Qiang ;
Cao, Xueying ;
Dumotier, Berengere ;
Fejzo, Jasna ;
Rajan, Srinivasan ;
Wang, Ping ;
Yan-Neale, Yan ;
Shao, Wenlin ;
Atadja, Peter ;
Shultz, Michael .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) :2952-2963
[7]   Phase I Pharmacokineitic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors [J].
de Bono, Johann S. ;
Kristeleit, Rebecca ;
Tolcher, Anthony ;
Fong, Peter ;
Pacey, Simon ;
Karavasilis, Vasilios ;
Mita, Monica ;
Shaw, Heather ;
Workman, Paul ;
Kaye, Stan ;
Rowinsky, Eric K. ;
Aherne, Wynne ;
Atadja, Peter ;
Scott, Jeffrey W. ;
Patnaik, Amita .
CLINICAL CANCER RESEARCH, 2008, 14 (20) :6663-6673
[8]   Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I [J].
Fouliard, Sylvain ;
Robert, Renata ;
Jacquet-Bescond, Anne ;
du Rieu, Quentin Chalret ;
Balasubramanian, Sriram ;
Loury, David ;
Loriot, Yohann ;
Hollebecque, Antoine ;
Kloos, Ioana ;
Soria, Jean-Charles ;
Chenel, Marylore ;
Depil, Stephane .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) :2791-2797
[9]   Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat) [J].
Furlan, Antonio ;
Monzani, Valmen ;
Reznikov, Leonid L. ;
Leoni, Flavio ;
Fossati, Gianluca ;
Modena, Daniela ;
Mascagni, Paolo ;
Dinarello, Charles A. .
MOLECULAR MEDICINE, 2011, 17 (5-6) :353-362
[10]   Click chemistry, a powerful tool for pharmaceutical sciences [J].
Hein, Christopher D. ;
Liu, Xin-Ming ;
Wang, Dong .
PHARMACEUTICAL RESEARCH, 2008, 25 (10) :2216-2230